Key Highlights
- Phathom reported record net Revenue of about $74.3 million, up about 88% year over year, driven by Voquezna prescription growth.
- Voquezna prescriptions filled reached about 325,000 in the quarter, up about 88%, with about 64% covered by payers.
- The company was essentially breakeven on a non-GAAP adjusted basis, a substantial improvement from the prior year.
- Phathom trimmed its full-year 2026 revenue guidance to about $310 million to $325 million, from about $320 million to $345 million.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a specialty pharmaceutical company commercializing its acid-suppression drug Voquezna, reported record revenue and rapid prescription growth in the second quarter and neared operating breakeven, though it trimmed its full-year revenue guidance.
Phathom Pharmaceuticals markets Voquezna, a potassium-competitive acid blocker approved for conditions such as erosive esophagitis and heartburn associated with non-erosive gastroesophageal reflux disease. Its results depend on the commercial ramp of Voquezna, its path toward profitability, its cash position, and its pipeline expansion.
Latest Developments
In its second-quarter 2026 results, Phathom reported record net revenue of about $74.3 million, up about 88% year over year and about 27% sequentially, with about 325,000 Voquezna prescriptions filled in the quarter, up about 88%, of which about 64% were covered. It posted a GAAP net loss of about $17.6 million but was essentially breakeven on a non-GAAP adjusted basis, a substantial improvement, and it held about $182.5 million in cash, which it expected, with its revenues, to fund its operating plan without additional financing.
However, it trimmed its full-year 2026 revenue guidance to about $310 million to $325 million, from about $320 million to $345 million. It also announced plans to initiate a registrational Phase 3 program evaluating vonoprazan for as-needed use in non-erosive GERD, with first enrollment expected in the fourth quarter of 2026.
Financial and Business Position
Phathom's record revenue, rapid prescription growth and near-breakeven non-GAAP results reflect a strengthening Voquezna launch and meaningful progress toward profitability, and its cash position reduces near-term funding risk. The considerations for investors are the trimmed revenue guidance, the reliance on the single Voquezna franchise, payer-coverage and pricing dynamics, competition in acid suppression, and the execution of the launch and the new Phase 3 program.
Stock-Market Context
In its latest close, PHAT stock fell 1.88%. That decline sits somewhat at odds with a quarter defined by 88% revenue growth and a move toward breakeven, suggesting the trimmed full-year guidance is weighing more heavily on sentiment than the underlying prescription momentum.
What Investors Should Watch
Investors may focus on Voquezna revenue, prescriptions and payer coverage, progress toward profitability, the cash position, the initiation of the as-needed GERD Phase 3 program, and performance against the trimmed guidance. Evidence that the Voquezna launch keeps accelerating toward sustained profitability while the new program advances would do the most to support the stock.
The Bottom Line
In its latest close, PHAT stock fell 1.88%, a decline that runs against a quarter of record revenue and rapid prescription growth for Voquezna. The stock's next move will likely depend on whether the launch can keep accelerating toward profitability even after the trimmed full-year guidance.






Please wait processing your request...